PMA device
Ats 3F Aortic Bioprosthesis Model 1000
Medtronic, Inc. · Heart-Valve, Non-Allograft Tissue (LWR, Class III) · First FDA decision Jul 13, 2010, newest Aug 21, 2019Aortic stenosisMitral regurgitationTricuspid regurgitation
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
5
Naming "Ats 3F"
MAUDE reports
0
Brand "Ats 3F", since 2015
PubMed studies
11
Mentioning "Ats 3F"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Ats 3F Aortic Bioprosthesis Model 1000
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- ATS 3F AORTIC BIOPROSTHESIS MODEL 1000PMA supplement
P060025-S002 · Decided Aug 21, 2019 · 3,920 days after receipt · Normal 180 Day Track No User Fee
Device type: heart-valve, non-allograft tissue (LWR) · Cardiology
- ATS 3F AORTIC BIOPROSTHESISPMA supplement
P060025-S009 · Decided Oct 26, 2012 · 179 days after receipt · Normal 180 Day Track No User Fee
Device type: heart-valve, non-allograft tissue (LWR) · Cardiology
- ATS 3F AORTIC BIOPROSTHESIS MODEL 1000PMA supplement
P060025-S005 · Decided Jul 13, 2010 · 60 days after receipt · Normal 180 Day Track No User Fee
Device type: heart-valve, non-allograft tissue (LWR) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Ats 3F", any status and sponsor, newest update first.
Medtronic CardiovascularPublic (MDT)
NCT01116024 · 173 participants · Start May 2006 · Primary completion Dec 2010
Device: ATS 3f Enable Aortic Bioprosthesis Model 6000 · For: Heart Valve Diseases
Sites: Vienna, Austria; Frankfurt, Germany; Freiburg im Breisgau, Germany · 10 sites in all
- Enable I Long-term Follow-up StudyTerminated
Medtronic Cardiac Rhythm and Heart FailurePublic (MDT)
NCT01636648 · 42 participants · Start Aug 2012 · Primary completion Apr 2016
Device: Aortic Valve Replacement · For: Aortic Valve Stenosis; Aortic Valve Insufficiency
Sites: Frankfurt, Germany; Freiburg im Breisgau, Germany; Kiel, Germany · 6 sites in all
Medtronic CardiovascularPublic (MDT)
NCT01116037 · 26 participants · Start Sep 2009 · Primary completion Nov 2015
Device: ATS 3f Aortic Bioprosthesis · For: Heart Valve Diseases
Sites: Oak Lawn, Illinois; New York, New York; Philadelphia, Pennsylvania · 6 sites in all
2 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Ats 3F", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code LWR
17,256 reports: 871 malfunction, 15,439 injury, 934 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Ats 3F"[tiab]. The summary above synthesizes these.
- Differential Immune Response to Bioprosthetic Heart Valve Tissues in the α1,3Galactosyltransferase-Knockout Mouse Model.
Casós K, Llatjós R, Blasco-Lucas A, et al. · Bioengineering (Basel) · 2023
- Transcatheter aortic valve-in-valve implantation in degenerative rapid deployment bioprostheses.
Landes U, Dvir D, Schoels W, et al. · EuroIntervention · 2019
- Clinical experience with the ATS 3f Enable® Sutureless Bioprosthesis.
Martens S, Sadowski J, Eckstein FS, et al. · Eur J Cardiothorac Surg · 2011Clinical Trial, Multicenter Study
- Antibody and Cellular Immune Responses in Old α1,3-Galactosyltransferase-Knockout Mice Implanted with Bioprosthetic Heart Valve Tissues.
Casós K, Llatjós R, Blasco-Lucas A, et al. · Bioengineering (Basel) · 2025
- Clinical experience with the ATS 3F stentless aortic bioprosthesis: five years' follow up.
Linneweber J, Heinbokel T, Christ T, et al. · J Heart Valve Dis · 2010
- [Sutureless aortic valve replacement for high surgical risk patients with aortic stenosis: systematic review].
Varela-Lema L, De La Fuente Cid R, López García ML · Med Clin (Barc) · 2013Systematic Review
- Fluid Dynamic Investigation of the ATS 3F Enable Sutureless Heart Valve.
Stühle S, Wendt D, Hou G, et al. · Innovations (Phila) · 2011
- Dedicated Transcatheter Valve for Pure Aortic Regurgitation in a Failed Stentless Bioprosthesis.
Corona S, Mrad S, Kouz R, et al. · JACC Case Rep · 2026Case Reports
- Diastolic properties of the Sorin Solo, ATS 3F, Edwards Prima Plus and Medtronic Freestyle stentless valves: an independent in-vitro comparison.
Weltert L, Nardella S, Girola F, et al. · J Heart Valve Dis · 2012Comparative Study
- Sutureless Aortic Valve Replacement via Partial Sternotomy.
Martens S, Zierer A, Ploss A, et al. · Innovations (Phila) · 2010
- Sutureless aortic valve replacement: catheter-based transapical versus direct transaortic implantation.
Doss M, Buhr E, Moritz A, et al. · J Heart Valve Dis · 2012Comparative Study
Other devices of this type
Also filed under product code LWR.
- Edwards Pericardial Aortic Bioprosthesis and INSPIRIS RESILIA Aortic ValveEdwards Lifesciences, LLC · PMA 2022
- St. Jude Medical Biocor and Biocor Supra ValvesAbbott Medical · PMA 2012
- INSPIRIS RESILIA Aortic ValveEdwards Lifesciences, LLC · PMA 2026
- Mitroflow Aortic Pericardial Heart ValveCorcym Canada Corp · PMA 2019
- TRIFORMIS RESILIA Tricuspid ValveEdwards Lifesciences, LLC · PMA 2026
- Perceval Sutureless Heart Valve, Perceval Plus Sutureless Heart ValveCorcym S.r.l. · PMA 2025
- Sjm Biocor Valve / Sjm Biocor Supra ValveAbbott Medical · PMA 2016
- Freestyle Aortic Root BioprosthesisMedtronic, Inc. · PMA 2013
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.